Driehaus Capital Management LLC Tricida, Inc. Transaction History

Driehaus Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $4.32 Million - $6.43 Million	-203,792 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$18.43 - $38.04 $1.12 Million - $2.31 Million	-60,742 Reduced 22.96%	203,792 $4.48 Million
Q4 2019 Feb 12, 2020	BUY	$29.6 - $43.71 $119,524 - $176,500	4,038 Added 1.55%	264,534 $9.98 Million
Q3 2019 Nov 14, 2019	SELL	$29.87 - $42.22 $2.42 Million - $3.43 Million	-81,176 Reduced 23.76%	260,496 $8.04 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $2.22 Million - $2.81 Million	71,308 Added 26.37%	341,672 $13.5 Million
Q1 2019 May 15, 2019	BUY	$19.96 - $38.62 $1.08 Million - $2.08 Million	53,984 Added 24.95%	270,364 $10.4 Million
Q4 2018 Feb 14, 2019	SELL	$23.57 - $32.33 $509,465 - $698,812	-21,615 Reduced 9.08%	216,380 $5.1 Million
Q3 2018 Nov 14, 2018	SELL	$22.5 - $39.35 $2.95 Million - $5.16 Million	-131,026 Reduced 35.51%	237,995 $7.27 Million
Q2 2018 Aug 14, 2018	BUY	$26.0 - $29.9 $9.59 Million - $11 Million	369,021 New	369,021 $11 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.